/f/125658/5000x1496/8aa45c8224/eacvi-acronym-text-rgb.png)
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Screening for amyloidosis in patients scheduled for aortic valve replacement
Event: Heart Failure 2024
Topic: Aortic Valve Intervention
Session: Interventional cardiology
Tolerance and clinical response to SGL2 inhibitors in Fabry disease
Event: Heart Failure 2024
Topic: Pharmacotherapy
Session: ePosters in chronic heart failure - pharmacotherapy 3
Mitral valve thickness: A promising echocardiographic parameter for distinguishing between cardiac amyloidosis and Fabry disease
Event: EACVI 2023
Topic: Myocardial Disease
Session: Cardiac Amyloidosis 2
New echocardiographic approaches to differentiate cardiac amyloidosis and Fabry disease: the right heart and mitral valve thickness
Event: ESC Congress 2022
Topic: Tissue Doppler, Speckle Tracking and Strain Imaging
Session: Risk stratification of cardiomyopathies with echocardiography
Case report on a transthyretin-related amyloidosis caused by Leu32Val mutation and its interdisciplinary challenge.
Event: ESC Congress 2021 - The Digital Experience
Topic: Myocardial Disease
Session: Acute and chronic heart failure
Impact of caval vein implantation on severity of tricuspid regurgitation, renal and hepatic function in patients with severe secondary tricuspid regurgitation
Event: ESC Congress 2020
Topic: Tricuspid Valve Intervention
Session: Novelty in Percutaneous Mitral and Tricuspid Valve Interventions
